TY - JOUR
T1 - Evaluation of an automated rapid diagnostic assay for detection of gram-negative bacteria and their drug-resistance genes in positive blood cultures
AU - Tojo, Masayoshi
AU - Fujita, Takahiro
AU - Ainoda, Yusuke
AU - Nagamatsu, Maki
AU - Hayakawa, Kayoko
AU - Mezaki, Kazuhisa
AU - Sakurai, Aki
AU - Masui, Yoshinori
AU - Yazaki, Hirohisa
AU - Takahashi, Hiroshi
AU - Miyoshi-Akiyama, Tohru
AU - Totsuka, Kyoichi
AU - Kirikae, Teruo
AU - Ohmagari, Norio
N1 - Funding Information:
H. Takahashi is a managing partner of East-West Diagnostics/Theranostics, LLC, and a consultant to Nanosphere. H. Takahashi has no other declarations relating to patents, products in development or marketed products. This study is not funded by these companies. The remaining authors have no reported potential conflicts of interest. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
PY - 2014/4/4
Y1 - 2014/4/4
N2 - We evaluated the performance of the Verigene Gram-Negative Blood Culture Nucleic Acid Test (BC-GN; Nanosphere, Northbrook, IL, USA), an automated multiplex assay for rapid identification of positive blood cultures caused by 9 Gram-negative bacteria (GNB) and for detection of 9 genes associated with β-lactam resistance. The BC-GN assay can be performed directly from positive blood cultures with 5 minutes of hands-on and 2 hours of run time per sample. A total of 397 GNB positive blood cultures were analyzed using the BC-GN assay. Of the 397 samples, 295 were simulated samples prepared by inoculating GNB into blood culture bottles, and the remaining were clinical samples from 102 patients with positive blood cultures. Aliquots of the positive blood cultures were tested by the BC-GN assay. The results of bacterial identification between the BC-GN assay and standard laboratory methods were as follows: Acinetobacter spp. (39 isolates for the BC-GN assay/39 for the standard methods), Citrobacter spp. (7/7), Escherichia coli (87/87), Klebsiella oxytoca (13/13), and Proteus spp. (11/11); Enterobacter spp. (29/30); Klebsiella pneumoniae (62/72); Pseudomonas aeruginosa (124/125); and Serratia marcescens (18/21); respectively. From the 102 clinical samples, 104 bacterial species were identified with the BC-GN assay, whereas 110 were identified with the standard methods. The BC-GN assay also detected all β-lactam resistance genes tested (233 genes), including 54 blaCTX-M, 119 blaIMP, 8 blaKPC, 16 blaNDM, 24 blaOXA-23, 1 blaOXA-24/40, 1 blaOXA-48, 4 blaOXA-58, and 6 blaVIM. The data shows that the BC-GN assay provides rapid detection of GNB and β-lactam resistance genes in positive blood cultures and has the potential to contributing to optimal patient management by earlier detection of major antimicrobial resistance genes.
AB - We evaluated the performance of the Verigene Gram-Negative Blood Culture Nucleic Acid Test (BC-GN; Nanosphere, Northbrook, IL, USA), an automated multiplex assay for rapid identification of positive blood cultures caused by 9 Gram-negative bacteria (GNB) and for detection of 9 genes associated with β-lactam resistance. The BC-GN assay can be performed directly from positive blood cultures with 5 minutes of hands-on and 2 hours of run time per sample. A total of 397 GNB positive blood cultures were analyzed using the BC-GN assay. Of the 397 samples, 295 were simulated samples prepared by inoculating GNB into blood culture bottles, and the remaining were clinical samples from 102 patients with positive blood cultures. Aliquots of the positive blood cultures were tested by the BC-GN assay. The results of bacterial identification between the BC-GN assay and standard laboratory methods were as follows: Acinetobacter spp. (39 isolates for the BC-GN assay/39 for the standard methods), Citrobacter spp. (7/7), Escherichia coli (87/87), Klebsiella oxytoca (13/13), and Proteus spp. (11/11); Enterobacter spp. (29/30); Klebsiella pneumoniae (62/72); Pseudomonas aeruginosa (124/125); and Serratia marcescens (18/21); respectively. From the 102 clinical samples, 104 bacterial species were identified with the BC-GN assay, whereas 110 were identified with the standard methods. The BC-GN assay also detected all β-lactam resistance genes tested (233 genes), including 54 blaCTX-M, 119 blaIMP, 8 blaKPC, 16 blaNDM, 24 blaOXA-23, 1 blaOXA-24/40, 1 blaOXA-48, 4 blaOXA-58, and 6 blaVIM. The data shows that the BC-GN assay provides rapid detection of GNB and β-lactam resistance genes in positive blood cultures and has the potential to contributing to optimal patient management by earlier detection of major antimicrobial resistance genes.
UR - http://www.scopus.com/inward/record.url?scp=84899049190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899049190&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0094064
DO - 10.1371/journal.pone.0094064
M3 - Article
C2 - 24705449
AN - SCOPUS:84899049190
SN - 1932-6203
VL - 9
JO - PloS one
JF - PloS one
IS - 4
M1 - e94064
ER -